Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price decreased by Barclays from $40.00 to $35.00 in a research note published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the company. BNP Paribas upgraded Revance Therapeutics from an […]
Related Keywords
United States , Markj Foley , Piper Sandler , Revance Therapeutics Company Profile , Thrivent Financial For Lutherans , Goldman Sachs Group , Revance Therapeutics Inc , Vanguard Group Inc , Nasdaq , Securities Exchange Commission , Goldman Sachs Group Inc , Barclays , Revance Therapeutics , Free Report , Moderate Buy , Therapeutics Trading Down , Get Free Report , Exchange Commission , Sigma Advisers , Sachs Group , Vanguard Group , Revance Therapeutics Daily , Nasdaq Rvnc , Rvnc , Medical , Lower Price Target , Barclays Plc ,
comparemela.com © 2020. All Rights Reserved.